InterCure Demonstrates Growth in First Half of 2025
InterCure Ltd. (NASDAQ: INCR) has unveiled its financial results for the first half of 2025, reporting an impressive NIS 130 million in revenue. This performance marks a significant turning point for the company, showcasing its resilience and sustained profitability by generating NIS 12 million in positive operating cash flow.
Revenue Growth and Operational Efficiency
Alexander Rabinovitch, the CEO of InterCure, highlighted the company’s achievement of positive Adjusted EBITDA for the eleventh consecutive half. "This performance underscores the strength of our vertically integrated business model and our capability to navigate through challenging circumstances," he stated. During this period, InterCure not only enhanced its revenue but also marked a 15% increase from the previous half.
Strategic Acquisitions Fueling Future Growth
Looking forward, InterCure is strategically positioned to take advantage of evolving opportunities in the global cannabis market. The recent signing of an agreement to acquire ISHI is expected to expand their reach, particularly within the U.S. market. The confidence in this acquisition stems from the anticipated benefits it may bring in terms of access to premium U.S. genetics and advanced cultivation technologies.
Financial Highlights of the First Half of 2025
Here are some key financial highlights for the first half of 2025:
- Revenue: NIS 130 million, a 15% increase compared to the second half of 2024, and a 3% rise from NIS 126 million in the first half of 2024.
- Net Loss: NIS 1.8 million, improved from near break-even in the same period last year.
- Adjusted EBITDA: NIS 12.6 million, representing 10% of total revenue.
- Operating Cash Flow: Positive cash flow of NIS 12 million, a notable recovery from negative cash flow of NIS 43 million in the prior year.
- Cash on Hand: NIS 54 million as of June 30, 2025, compared to NIS 21 million at the same time last year.
- Shareholders’ Equity: NIS 432 million as of June 30, 2025.
Operational Progress Amid Challenging Conditions
The company has resumed production, importation, and sales from its Nir Oz facility, recovering from setbacks due to the impact of recent geopolitical events. Since then, more than 40 new products were launched, contributing to meeting the growing demand for its high-quality cannabis products.
Regulatory Developments and Future Expectations
Furthermore, InterCure is closely monitoring developments in U.S. cannabis regulations, especially regarding potential rescheduling. The company is well prepared to adapt and benefit from these changes as they occur. Rabinovitch emphasized the importance of these developments for their strategic positioning within the market.
About InterCure
InterCure (dba Canndoc) is the fastest-growing cannabis company outside of North America and the leading licensed cannabis producer in Israel. With its commitment to quality and compliance, InterCure has built a strong distribution network and has established itself as a key player in the pharmaceutical cannabis industry.
Frequently Asked Questions
What were InterCure's total revenues for H1 2025?
InterCure reported total revenues of NIS 130 million for the first half of 2025.
How does InterCure's new acquisition of ISHI affect its growth strategy?
The acquisition of ISHI is expected to enhance InterCure's access to premium U.S. genetics, thereby expanding its market opportunities and strengthening its competitive edge.
What is InterCure's approach to dealing with recent geopolitical issues?
InterCure has focused on resuming production and sales from its facilities and is working closely with local authorities to seek compensation for damages incurred during recent events.
Who is the CEO of InterCure?
Alexander Rabinovitch is the CEO of InterCure, guiding the company through its recovery and growth strategies.
How does InterCure define Adjusted EBITDA?
Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation, and amortization, adjusted for specific changes and other items as determined by the company.
